- Home
- TRX vs AGEN Comparison
TRX vs AGEN Comparison
Compare TRX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- AGEN
- Stock Information
- Founded
- TRX 1990
- AGEN 1994
- Country
- TRX Canada
- AGEN United States
- Employees
- TRX N/A
- AGEN N/A
- Industry
- TRX
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRX
- AGEN Health Care
- Exchange
- TRX Nasdaq
- AGEN Nasdaq
- Market Cap
- TRX 94.5M
- AGEN 87.7M
- IPO Year
- TRX N/A
- AGEN 2000
- Fundamental
- Price
- TRX $0.34
- AGEN $7.27
- Analyst Decision
- TRX Strong Buy
- AGEN Buy
- Analyst Count
- TRX 1
- AGEN 4
- Target Price
- TRX $1.50
- AGEN $13.00
- AVG Volume (30 Days)
- TRX 404.8K
- AGEN 1.4M
- Earning Date
- TRX 07-22-2025
- AGEN 08-07-2025
- Dividend Yield
- TRX N/A
- AGEN N/A
- EPS Growth
- TRX N/A
- AGEN N/A
- EPS
- TRX N/A
- AGEN N/A
- Revenue
- TRX $45,405,000.00
- AGEN $99,524,000.00
- Revenue This Year
- TRX $51.45
- AGEN $12.69
- Revenue Next Year
- TRX $26.19
- AGEN N/A
- P/E Ratio
- TRX N/A
- AGEN N/A
- Revenue Growth
- TRX 26.50
- AGEN N/A
- 52 Week Low
- TRX $0.27
- AGEN $1.38
- 52 Week High
- TRX $0.45
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- TRX 54.18
- AGEN 68.42
- Support Level
- TRX $0.33
- AGEN $4.78
- Resistance Level
- TRX $0.35
- AGEN $6.20
- Average True Range (ATR)
- TRX 0.01
- AGEN 0.62
- MACD
- TRX -0.00
- AGEN 0.10
- Stochastic Oscillator
- TRX 50.50
- AGEN 98.90
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).